CNTA — Centessa Pharmaceuticals PLC ADR

✨ Hidden Gem

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Centessa Pharmaceuticals PLC ADR

Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$39.77
Market Cap$6.16B
Float92.5M
Shares Outstanding154.7M
Price/Sales (TTM)409.21
vs. Analyst Target+12.1% to analyst PT
Dividend RateNone
Analyst Target Price$44.57 (11 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 N/A -$10.7M N/A -$10.3M
2021 N/A -$382M -$33,995 -$139M
2022 N/A -$216M -$131,000 -$210M
2023 $6.9M -$151M $6.9M -$165M
2024 N/A -$236M -$942,396 -$222M
2025 $15.0M -$198M $15.0M -$208M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 N/A -$50.3M
Sep 2025 N/A -$54.9M
Dec 2025 N/A -$66.2M
Mar 2026 N/A -$79.2M

Ownership & Float

Insider Ownership0.5%
Institutional Ownership99.8%
Short Float3.0%
% of All Funds Holding1.83%
Number of Funds Holding150

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$38.53Near-term / short-term trend
Weekly40-Week SMA$27.84Medium-term trend
Weekly80-Week SMA$21.55Cyclical trend (business cycle)
Weekly200-Week SMA$13.11Secular trend (multi-year)
Monthly10-Month SMA$29.03Near-term monthly trend
Monthly20-Month SMA$22.22Medium-term monthly trend
Monthly40-Month SMA$15.16Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$26.70 support 2.38x 1 months ago
$16.80 support 1.54x 7 months ago
$13.10 support 1.35x 9 months ago
$10.60 support 1.47x 20 months ago
$9.00 support 1.08x 21 months ago

Historical Earnings Reactions (21 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 0.83% 0.77% 61.90% 3.85% -2.11%
1 Day 1.42% 0.18% 57.14% 14.44% -9.89%
1 Week 0.56% 0.97% 55.00% 34.93% -20.44%
2 Weeks 2.57% 2.49% 60.00% 34.59% -35.60%
1 Month 5.36% 0.56% 50.00% 49.50% -17.08%

Next earnings: May 18, 2026

Seasonality & Day-of-Week Patterns

Monthly Seasonality

Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday -0.60% 40.9% 232
Tuesday 0.78% 50.0% 260
Wednesday 0.26% 49.4% 257
Thursday -0.06% 50.4% 250
Friday 0.29% 51.4% 253

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 99.8%

Insider Transactions — Smart Summary

Total insider ownership: 0.5%

12-Month Insider Activity Summary

Total Filings29
Net Value-$18.2M
Net Shares Change-118,693
% of Float-0.1%
C-Suite Filings29
Clusters Detected3

Key Insiders

NameTitleNet ValueFilingsActivity
Anderson Karen M. Chief People Officer -$8.1M 4 N/A
Weinhoff Gregory M Chief Business Officer -$1.9M 1 N/A
HUSSAIN IQBAL J Chief Legal Officer -$1.2M 1 1 sell
Accardi Mario Alberto President, Orexin Program -$842,236.195 4 N/A

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-06-20 – 2025-06-25 4 4 -$833,606.4 4 C-suite
2025-07-17 – 2025-07-30 4 4 -$962,225.518 4 C-suite
2025-09-11 – 2025-09-24 6 3 -$2.1M 6 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-02-03 HUSSAIN IQBAL J Chief Legal Officer -$1.2M Transaction at $24.86, now +60.0%
2026-03-16 Anderson Karen M. Chief People Officer -$2.7M Transaction at $15.12, now +163.1%
2026-03-13 Weinhoff Gregory M Chief Business Officer -$1.9M Transaction at $26.33, now +51.1%
2026-03-13 Anderson Karen M. Chief People Officer -$2.7M Transaction at $15.13, now +162.9%
2025-12-09 Accardi Mario Alberto President, Orexin Program -$288,289 Transaction at $28.83, now +38.0%
2025-12-08 Accardi Mario Alberto President, Orexin Program -$252,350 Transaction at $19.77, now +101.2%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Centessa Pharmaceuticals PLC ADR (CNTA) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for CNTA on Trend Edge →